Oxford based Immunocore is an emerging UK biotechnology company that should be on your radar if you’re following companies such as Kite Pharmaceuticals and Juno Therapeutics. If it isn’t already you can expect to hear a lot more about them in the forthcoming year as they start clinical trials with the many leading global pharma companies who have already partnered with them.

Dr Namir Hassan, Immunocore

Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.

Namir Hassan, D.Phil (pictured right) is Director of Translational Research and Head of Development at Immunocore. BSB met with him and Chief Business Officer, Eva-Lotta Allan at the company offices located in a science and business park near Oxford.

Immunocore recently raised $320M in Europe’s largest private life sciences funding. (Link to Press Release)

Earlier this year preliminary clinical data for IMCgp100 their first-in-class novel immunotherapy was presented at the annual meeting of the American Association for Cancer Research (AACR) in Philadelphia by Mark Middleton, Professor of Experimental Cancer Medicine at the University of Oxford.

In the interview, excerpts of which you can read below, Dr Hassan explained why their exciting and innovative approach that targets the T Cell Receptor is different from other companies in the field, what they have learned from the preliminary clinical data, and the potential immTACs may offer in combination with other cancer immunotherapies.

If you’re not a cancer immunologist, this type of science is complex, so the aim of the interview was to put into context the data already in the public domain and gain some insights into the excitement behind ImmTACs and what immunocore are doing. If you don’t understand the potential of TCRs and ImmTACs as immunotherapies, this post is for you!

Subscribers can login to read more, or you can purchase access below.

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTs & WRITERs), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.